Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Aspirin May Reduce Colon Cancer Chances

October 22, 2010 5:46 am | by Maria Cheng | News | Comments

A new analysis suggests that taking a low dose of aspirin may modestly reduce the risk of developing colon cancer. But experts say aspirin's side effects of bleeding and stomach problems are too worrisome for most people to take the drug for that reason alone.

TOPICS:

Stent-Coating System

October 21, 2010 8:50 am | Product Releases | Comments

Sono-Tek Corporation has launched the 180kHz nozzle upgrade for its MediCoat DES 1000 and MediCoat II anti-restinosis stent coating systems. The 180 kHz ultrasonic nozzle creates a drop several microns smaller than that of the typically used 120 kHz nozzle.

TOPICS:

Human Umbilical Vein Endothelial Cells

October 21, 2010 8:42 am | Drug Discovery & Development | Product Releases | Comments

American Type Culture Collection , a bioresource center, offers human umbilical vein endothelial cells (HUVEC) as part of its Primary Cell Solutions for cardiovascular research.

TOPICS:
Advertisement

Link Between 2 Forms of ALS Suggests Drug Target

October 21, 2010 8:16 am | News | Comments

For the first time, researchers have discovered a disease mechanism that links hereditary amyotrophic lateral sclerosis to the more common "sporadic" form of ALS -- and points to a possible therapeutic target.

TOPICS:

Redeeming Roll for Reovirus

October 21, 2010 8:14 am | News | Comments

A common virus that can cause coughing and mild diarrhea appears to have a major redemptive quality: the ability to kill cancer. Harnessing that power, researchers are conducting a clinical trial to see if the virus can target and kill certain tumor types.

TOPICS:

'Reaper' Protein Strikes at Mitochondria

October 21, 2010 8:11 am | News | Comments

Cells require the a team of molecules to prevent them from destroying themselves. This self-destructive tendency can be a good thing, as when dangerous precancerous cells are permitted to kill themselves, but it can also go horribly wrong.

TOPICS:

Black Rice Reduces Inflammation

October 21, 2010 8:03 am | News | Comments

Scientists are reporting evidence that black rice — a little-known variety of the grain that is the staple food for one-third of the world population — may help soothe the inflammation involved in allergies, asthma, and other diseases.

TOPICS:

New Odanacatib Data Presented at ASBMR

October 21, 2010 8:00 am | News | Comments

New data presented at the 32nd Annual Meeting of The American Society for Bone and Mineral Research provided further information on the potential of odanacatib to increase bone density, cortical thickness and bone strength when treating osteoporosis.

TOPICS:
Advertisement

Cytheris Announces Phase 2 Trial of CYT107

October 21, 2010 7:56 am | News | Comments

Cytheris SA announced the initiation of Phase 2 clinical trial of the company’s investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs, raltegravir and maraviroc.

TOPICS:

Gilead Revenues Up 8%

October 21, 2010 7:52 am | News | Comments

Gilead Sciences, Inc. announced its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009.

TOPICS:

GSK Developing Gene Therapies

October 21, 2010 7:49 am | News | Comments

GlaxoSmithKline announcement to develop and market gene therapy treatments for rare genetic disorders signals a “next step” for the field of gene therapy, according to the American Society of Gene & Cell Therapy.

TOPICS:

ImmuPharma Filing IND for IPP-204106

October 21, 2010 6:58 am | News | Comments

ImmuPharma plans to file a US IND in the next few months and to commence a Phase 2b program the first half of 2011 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer and pancreatic cancer.

TOPICS:

Earlier Use of Copaxone Leads to Better Outcomes

October 21, 2010 6:40 am | News | Comments

Teva Pharmaceutical Industries Ltd. announced new data from the PreCISe study demonstrating that earlier initiation of treatment with Copaxone in patients presenting with first signs of multiple sclerosis provided greater effects.

TOPICS:

USPTO Awards Metabolon Biomarker Patent

October 21, 2010 6:34 am | News | Comments

Metabolon, Inc., a leader in global metabolomics, biomarker discovery and biochemical analysis, announced that the United States Patent and Trademark Office has granted patent 7,807,138 entitled “Biomarkers of Metabolic Responses to Hepatic Drugs”.

TOPICS:

FDA Approves Herceptin for Metastatic Stomach Cancer

October 21, 2010 6:30 am | News | Comments

Genentech announced the Food and Drug Administration has approved Herceptin with chemotherapy for HER2-positive metastatic cancer of the stomach or gastroesophageal junction, for patients who have not been treated for their metastatic disease.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading